NCT03980080View on ClinicalTrials.gov

Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

November 4, 2019

Study Completion Date

November 4, 2019

Conditions
Healthy Subjects
Interventions
DRUG

OSE-127

"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 1-7~6 escalating dose level groups IV~SC"

DRUG

Placebo

Vehicle study drug

DRUG

OSE-127

"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 8-9~2 escalating dose level groups IV"

Trial Locations (1)

2060

SGS Life Sciences (SGS LS), Clinical Pharmacology Unit (CPU), Antwerp

Sponsors
All Listed Sponsors
collaborator

Servier

INDUSTRY

lead

OSE Immunotherapeutics

INDUSTRY

NCT03980080 - Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects | Biotech Hunter | Biotech Hunter